Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Achaogen Inc (AKAO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 504,017
  • Shares Outstanding, K 42,390
  • Annual Sales, $ 41,770 K
  • Annual Income, $ -71,230 K
  • 36-Month Beta 1.43
  • Price/Sales 12.01
  • Price/Cash Flow 0.00
  • Price/Book 3.26

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.13 +9.16%
on 11/20/17
14.85 -18.18%
on 11/09/17
-1.73 (-12.46%)
since 10/20/17
3-Month
11.13 +9.16%
on 11/20/17
19.74 -38.45%
on 08/28/17
-6.33 (-34.25%)
since 08/21/17
52-Week
4.73 +156.87%
on 11/22/16
27.79 -56.28%
on 03/13/17
+7.28 (+149.49%)
since 11/21/16

Most Recent Stories

More News
Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update

/p>

AKAO : 12.42 (+4.46%)
Achaogen to Present at the Stifel 2017 Healthcare Conference

-- Company presentation scheduled for November 14, 2017 at 8:45 a.m. EST --

AKAO : 12.42 (+4.46%)
Achaogen to Host Conference Call and Webcast of Third Quarter 2017 Financial Results on November 8, 2017

Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced...

AKAO : 12.42 (+4.46%)
Achaogen Announces New Employment Inducement Grants

Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on October...

AKAO : 12.42 (+4.46%)
Achaogen Submits Plazomicin New Drug Application (NDA) to the U.S. FDA for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections

/p>

AKAO : 12.42 (+4.46%)
Biotech Stock Performance Review -- Cyclacel Pharma, TG Therapeutics, Vericel, and Achaogen

If you want a Stock Review on CYCC, TGTX, VCEL, or AKAO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. This morning's attention is redirected to the...

TGTX : 7.62 (-1.04%)
AKAO : 12.42 (+4.46%)
CYCC : 1.83 (+5.78%)
VCEL : 3.95 (+2.60%)
Achaogen IDWeek 2017 Presentations Feature Plazomicin's Unique Potential to Treat MDR Enterobacteriaceae

/p>

AKAO : 12.42 (+4.46%)
Achaogen Awarded up to $18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape

Non-dilutive funding to support clinical development of antibacterial candidate for ESBL infections

AKAO : 12.42 (+4.46%)
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017

Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multidrug-resistant (MDR) gram-negative infections, today announced five upcoming presentations...

AKAO : 12.42 (+4.46%)
Achaogen Announces New Employment Inducement Grants

Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on September...

AKAO : 12.42 (+4.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment...

See More

Key Turning Points

2nd Resistance Point 12.49
1st Resistance Point 12.19
Last Price 12.42
1st Support Level 11.36
2nd Support Level 10.83

See More

52-Week High 27.79
Fibonacci 61.8% 18.98
Fibonacci 50% 16.26
Fibonacci 38.2% 13.54
Last Price 12.42
52-Week Low 4.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart